Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 10/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Axitirome SCHEMBL29381397 | 1.00 | THRA (1.00) | THRATHRBMAPT | |
| SCHEMBL8800061 | 0.92 | THRA (0.86) | THRATHRB | |
| SCHEMBL8800186 | 0.91 | THRA (0.83) | THRATHRB | |
| SCHEMBL8800713 | 0.90 | THRA (0.82) | THRATHRB | |
| SCHEMBL8798400 | 0.89 | THRA (0.80) | THRATHRBMAPT | |
| SCHEMBL3866533 | 0.88 | THRA (0.79) | THRATHRB | |
| SCHEMBL7213670 | 0.85 | THRA (0.73) | THRATHRB | |
| SCHEMBL1642443 | 0.85 | THRA (0.73) | THRATHRB | |
| SCHEMBL8798722 | 0.84 | THRA (0.76) | THRATHRB | |
| SCHEMBL4965095 | 0.84 | THRA (0.72) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000836-A1 | PARTICLE DELIVERY OF THYROID HORMONE RECEPTOR AGONISTS AND ANTAGONISTS | CYTA THERAPEUTICS INC (US) | 2025-01-02 | — | — | US | claimed |
| EP-4373476-A1 | PARTICLE DELIVERY OF THYROID HORMONE RECEPTOR AGONISTS AND ANTAGONISTS | Cyta Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| WO-2023004002-A1 | PARTICLE DELIVERY OF THYROID HORMONE RECEPTOR AGONISTS AND ANTAGONISTS | CYTA THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | WO | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2011-09-01 | — | — | US | claimed |
| CN-102149282-A | Carbonate prodrugs and methods of using the same | NEUROGESX INC | 2011-08-10 | — | — | CN | claimed |
| EP-2291084-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | Neurogesx, Inc. (US) | 2011-03-09 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1036564-B1 | Thyromimetic antiobesity agents | PFIZER PROD INC (US) | 2004-11-17 | — | — | EP | claimed |
| US-20020035153-A1 | Thyromimetic antiobesity agents | CORNELIUS PETER (US) | 2002-03-21 | — | — | US | claimed |
| US-6344481-B1 | Thyromimetic antiobesity agents | PFIZER INC. | 2002-02-05 | — | — | US | claimed |
| EP-1036564-A1 | Thyromimetic antiobesity agents | Pfizer Products Inc. (US) | 2000-09-20 | — | — | EP | claimed |
| EP-0580550-B1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA GEIGY AG (CH) | 1997-10-22 | — | — | EP | claimed |
| US-5569674-A | ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-10-29 | — | — | US | claimed |
| US-5401772-A | Anticholesterol agents with aromatic amines | CIBA-GEIGY CORPORATION (US) | 1995-03-28 | — | — | US | claimed |
| EP-0580550-A1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA-GEIGY AG (CH) | 1994-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000836-A1 | PARTICLE DELIVERY OF THYROID HORMONE RECEPTOR AGONISTS AND ANTAGONISTS | TSHR, TRHR, THRB | THRA 4/4885THRB 3/4885MAPT 2243/4885 |
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | THRA 1805/4885THRB 2407/4885MAPT 3060/4885 |
| US-20020035153-A1 | Thyromimetic antiobesity agents | GPR119, TRHR, TSHR | THRA 5/4885THRB 6/4885MAPT 4767/4885 |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | THRA 1805/4885THRB 2407/4885MAPT 3060/4885 |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | THRA 1805/4885THRB 2407/4885MAPT 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.